Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

NCT00430443 | Terminated Phase 1

• 1 other identifier: CP-105
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 3

Brief Summary

This is a Phase I, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML. Enrollment will occur in cohorts of approximately 3 subjects with 10 additional subjects enrolled at the MTD. The liposomal annamycin doses will be escalated in sequential cohorts. Six dose levels of liposomal annamycin are planned: 130, 160, 190, 230, 280, and 310 mg/m2/day.The primary objectives of this study are 1) to evaluate the safety and identify the maximum tolerated dose (MTD) of liposomal annamycin when given in 3 consecutive daily doses, starting at 130 mg/m2/day and ranging to as high as 310 mg/m2/day, or the MTD, whichever is lower, in children and young adults with refractory or relapsed acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML), and 2) to evaluate the antileukemic activity of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML. The secondary objective is to measure the pharmacokinetics of annamycin and its metabolite, annamycinol.

Conditions

Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia

Keywords

Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Annamycin; Liposomal Annamycin

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and identify the MTD of liposomal annamycin and to evaluate the antileukemic activity of liposomal annamycin in children and young adults.

  8 months

Secondary Outcomes (1)

• To measure the pharmacokinetics of annamycin and its metabolite, annamycinol.

  8 months

Interventions

Liposomal Annamycin DRUG

3-day IV infusion

Eligibility Criteria

• Age: 12 Months - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Diagnosis of refractory or relapsed ALL or AML.
• months to 21 years of age at the time of informed consent.
• Weight ≥10 kg
• No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from the toxic side effects of such therapy. In the instance of rapidly progressive disease, anti-leukemia therapy may be administered within the 2-week period as long as the subject has recovered from the toxic effects of that therapy. Also, intrathecal therapy may be administered within the 2-week period for subjects with CNS disease.
• No stem cell transplant regimen within 3 months prior to first dose of study drug.
• No conventional granulocyte colony stimulating factor (G-CSF) within 7 days prior to the first dose of study drug, and no long-acting G-CSF (Neulasta) within 14 days prior to the first dose of study drug.
• No investigational therapy within 4 weeks prior to first dose of study drug.
• Karnofsky Performance Status ≥50% for subjects ≥10 years of age and Lansky Performance Status ≥60% for subjects \<10 years of age. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance status.
• Adequate liver function \[bilirubin ≤2 times the upper limit of normal (ULN) and serum glutamic-pyruvic transaminase (SGPT) ≤5 times the ULN\].
• Adequate renal function (creatinine clearance ≥60 ml/min/1.73m2).
• Adequate cardiac function \[ejection fraction (EF) \>50% or shortening fraction (SF) \>28% by echocardiogram or MUGA\]
• Informed consent signed by subject or legal guardian per investigational site guidelines.
• Able to comply with the requirements of the protocol.
• Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to first dose of study drug.
• All subjects (male and female) of childbearing potential must agree to practice effective contraception during the entire study period, unless documentation of infertility exists. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

You may not qualify if:

• Concomitant therapy that includes other chemotherapy that is or may be active against ALL or AML, except for prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals and/or antiviral agents. Concurrent radiation therapy and immunosuppressive therapy are not allowed. Concurrent intrathecal therapy per standard of care is allowed for subjects with CNS disease.
• Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
• Clinically relevant serious co-morbid medical conditions including, but not limited to, active infection, recent (≤6 months) myocardial infarction, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements. Cardiac patients with a New York Heart Association (NYHA) classification of 3 or 4 will be excluded.
• Active graft-versus-host disease (GVHD).
• Pregnant, lactating, or not using adequate contraception.
• Known allergy to doxorubicin or anthracyclines.
• Any evidence of mucositis/stomatitis, except for Grade 1 mucositis/stomatitis due to chronic GVHD.

Sponsors & Collaborators

• Callisto Pharmaceuticals: lead

Study Sites (3)

Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States

Location

Denver Children's Hospital

Denver, Colorado, 80218, United States

Location

Vanderbilt Children's Hospital

Nashville, Tennessee, 37237, United States

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, Myeloid

Study Officials

• Gary Jacob, Ph.D.

  Callisto Pharmaceuticals, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 30, 2007
• First Posted: February 1, 2007
• Study Start: February 1, 2007
• Study Completion: January 1, 2009
• Last Updated: August 31, 2011

Record last verified: 2011-08

Locations

US (3)